We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

34 hedge funds and large institutions have $4.09M invested in Acorda Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more capital invested

Capital invested by funds: $1.91M → $4.09M (+$2.18M)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

3% more funds holding

Funds holding: 33 → 34 (+1)

62% less call options, than puts

Call options by funds: $25K | Put options by funds: $66K

Holders
34
Holders Change
+1
Holders Change %
+3.03%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
9
Reduced
8
Closed
3
Calls
$25K
Puts
$66K
Net Calls
-$41K
Net Calls Change
-$43K

Top Buyers

1
TI
Telemetry Investments
New York
+$77.2K
2
TSS
Two Sigma Securities
New York
+$73.9K
3
Deutsche Bank
Deutsche Bank
Germany
+$19.8K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.2K
5
Simplex Trading
Simplex Trading
Illinois
+$10.6K

Top Sellers

1
CCA
Canyon Capital Advisors
Texas
-$357K
2
Prudential Financial
Prudential Financial
New Jersey
-$16.8K
3
BCM
Bridgeway Capital Management
Texas
-$14.6K
4
VF
Virtu Financial
New York
-$6K
5
TRCT
Tower Research Capital (TRC)
New York
-$5.57K
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$1.82M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$666K +$7.63K +655 +2%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$522K – – –
Millennium Management
4
Millennium Management
New York
$151K +$4.2K +360 +4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$121K +$1.77K +152 +2%
TSS
6
Two Sigma Securities
New York
$115K +$73.9K +6,339 +554%
BlackRock
7
BlackRock
New York
$104K -$105 -9 -0.1%
TI
8
Telemetry Investments
New York
$102K +$77.2K +6,625 New
SC
9
Saltoro Capital
Texas
$83.4K – – –
BCM
10
Bridgeway Capital Management
Texas
$58.8K -$14.6K -1,250 -25%
Wells Fargo
11
Wells Fargo
California
$57.3K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$51K +$12.2K +1,047 +45%
Deutsche Bank
13
Deutsche Bank
Germany
$26.1K +$19.8K +1,700 New
State Street
14
State Street
Massachusetts
$24.3K – – –
Prudential Financial
15
Prudential Financial
New Jersey
$24.1K -$16.8K -1,440 -48%
Two Sigma Investments
16
Two Sigma Investments
New York
$22.4K +$443 +38 +3%
UAS
17
United Asset Strategies
New York
$20.8K – – –
Northern Trust
18
Northern Trust
Illinois
$20K – – –
Simplex Trading
19
Simplex Trading
Illinois
$19K +$10.6K +911 +264%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$17.7K -$1.27K -109 -9%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$11.5K +$117 +10 +1%
SQA
22
Simon Quick Advisors
New Jersey
$10.9K – – –
Verition Fund Management
23
Verition Fund Management
Connecticut
$10.5K – – –
UBS Group
24
UBS Group
Switzerland
$10.2K +$723 +62 +10%
Group One Trading
25
Group One Trading
Illinois
$7.32K +$5.56K +477 New
1
2

ACOR Hedge Fund Activity: Q4 2022 in Review

34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2022, worth a combined $4.09M — up 114% from $1.91M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ACOR positions and 3 closed out — a net gain of 1 holder — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Telemetry Investments, opening a new position worth an estimated $77.2K. The largest seller was Canyon Capital Advisors, exiting entirely with an estimated $357K sold.

  • 34 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2022, up from 33 in Q3 2022.
  • Funds reported $4.09M of Acorda Therapeutics stock for Q4 2022, up 114% quarter-over-quarter.
  • 4 funds opened new Acorda Therapeutics positions in Q4 2022 and 3 closed out, a net change of +1 holder.
  • The largest Acorda Therapeutics buyer in Q4 2022 was Telemetry Investments, an estimated $77.2K added.
  • The largest Acorda Therapeutics seller in Q4 2022 was Canyon Capital Advisors, an estimated $357K sold.

Based on aggregated 13F filings for Q4 2022.